A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

(2018) Eli Muchtar et al.   LEUKEMIA

Systemic amyloidosis

(2016) Ashutosh D Wechalekar et al.   LANCET

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

(2016) H Landau et al.   LEUKEMIA

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

(2015) Efstathios Kastritis et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

(2015) V. Sanchorawala et al.   BLOOD

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

(2015) G. Palladini et al.   BLOOD

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

(2014) A. Jaccard et al.   HAEMATOLOGICA

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

(2014) C P Venner et al.   LEUKEMIA

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

(2013) A. D. Wechalekar et al.   BLOOD

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

(2012) C. P. Venner et al.   BLOOD

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

(2012) Giovanni Palladini et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

(2012) R L Comenzo et al.   LEUKEMIA

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

(2011) M. T. Cibeira et al.   BLOOD

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

(2010) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

(2010) Efstathios Kastritis et al.   JOURNAL OF CLINICAL ONCOLOGY

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD